Arginine Glycine Aspartic Acid Motif Peptide Potentiates the Effect of Oxaliplatin Preventing Colon Cancer Metastasis, Binds to α5 β1 Integrin and Suppresses FAK/ERK/NF-kB Signaling
Lunasin is a promising chemopreventive agent. The objective was to study the effect of lunasin on human colon cancer metastasis using in vitro and in vivo colon cancer model of liver metastasis. Lunasin inhibited the activation of focal adhesion kinase by 28%, 39% and 60% in RKO, HCT-116 and KM12L4 human colon cancer cells, respectively. Lunasin caused an increase in the expression of the inhibitor of kappa B alpha, a decrease in nuclear p50 NF-kB and a reduction in the migration of cancer cells. Lunasin inhibited metastasis and potentiated the effect of oxaliplatin by reducing the expression of proliferating cell nuclear antigen. Liver metastatic nodules were reduced from 28 (PBS) to 14 (lunasin, p = 0.047) while combination of lunasin and oxaliplatin to 5 (p = 0.004). The tumor burden was reduced from 0.13 (PBS) to 0.10 (lunasin, p = 0.039) to 0.04 (lunasin-oxaliplatin, p less than 0.0001). The effect of oxaliplatin in modifying the expression of proteins involved in apoptosis and metastasis was potentiated by lunasin. Lunasin inhibited metastasis by direct binding with alpha-5 beta-1 integrin suppressing FAK/ERK/NF-kB signaling, and potentiated the effect of oxaliplatin in preventing the outgrowth of metastasis.
Good morning.
Thank you for the opportunity to present our work today.
Dr. Bermondia did most of this work and now he's a doctor and he did this work during
his PhD training.
In our laboratory, we study compounds in the food that may prevent some types of cancer.
So we use in vitro and in vivo models.
Today I'm going to present some results of one of the peptides naturally present in foods
that has some effect on colon cancer.
So the statistics from 2012 show that 1.2 million new cases of colorectal cancer were
present in 2008.
We know that patients mainly die, 90% of them due to a liver metastasis.
Protein contains different bioactive compounds and there are several meta-analyses showing
that soy consumption may be associated to a reduction of colorectal cancer.
There are newer studies insisting on around 10 grams of soy protein per day and maybe
35 milligrams per day of isoflavone may have an effect on lowering the risk of colorectal
cancer.
There are several compounds, sorry I deleted that but it's still there, okay.
There are different compounds in soybean but today I'm going to introduce to you one naturally
present peptide that we have been working with in the last few years, it's called lunacin.
Let me show you, lunacin is a 43 amino acid peptide that has two unique characteristics.
One of them is the tail of 9 aspartic acids and one is the motif which is arginine glycine
aspartic acid.
It is believed that this tail of aspartic acids directly binds to core histones and
then produces the death of the cells and also there is a motif, as I told you before, RGD
motif that helps internalize it into the cell.
So there are many unknowns on this protein, however there are already some preliminary
data on skin cancer showing that as you increase the concentration from 2.5 micrograms per
week to maybe 250 micrograms per week on the skin, the tumor incidence decreases as you
can see here.
Also for breast cancer it has been shown that as you increase the concentration of lunacin
from 20 milligrams per kilogram, the decrease in incidence of these tumors is more pronounced.
Remember that 25 grams of soy protein per day will give you 4 milligrams of lunacin
per day.
So our hypothesis is that lunacin purified from soybean, lunacin is present in soy but
also in some cereals, will mediate colorectal cancer by promoting apoptosis by virtue of
its RGD motif, preventing the outgrowth of metastasis, blocking the integrin signaling.
And our preliminary data has shown that the main integrin that has been modified by the
presence of lunacin is alpha 5 beta 1 integrin.
So we want to provide a molecular mechanism by which lunacin can mediate the process of
colorectal cancer in vivo and in vitro.
So today I'm going to share with you some results of eight different human colon cancer
cells provided by the MD Anderson Cancer Center, Dr. Lee Ellis provided all of these cells.
We of course studied some of the proliferation, apoptosis, cell cycle, and very importantly
we studied some of these integrins to identify the potential interaction between lunacin
and integrins as initial potential targets of metastasis.
So we also run an in vivo study with a CRC liver metastasis model and we use lunacin,
we use oxaliplatin, 5 milligrams per kilogram twice weekly, and then we use a combination
of lunacin, 4 milligrams per kilogram per day, and oxaliplatin in the same concentration.
So we'll see some of the results.
For non-resistant human colon cancer cells, we saw that even at 5 micromolar, some of
the more metastatic cells start dying, the viability start decreasing.
For the more metastatic cancer cells and resistant to oxaliplatin, we also notice a decrease
in cell viability starting at 25 micrograms of lunacin.
So this in particular, KM12L4 oxaliplatin resistant, we took it and continue working
with that cell.
Very interestingly, when we combine 0.5 micromolars of oxaliplatin with different concentrations
of lunacin, we saw a very clear synergistic effect.
For instance, if you take a look at the 2 micromolar of oxaliplatin and 10 micromolar
of lunacin, you can see a very considerable reduction, is this last one, for 25 micromolar
in the cell viability.
This is a summary of IC50s in micromolar of all of these cells, and also very interestingly,
we saw a direct correlation with the presence of integrins, alpha-5, beta-1 integrin.
There was a very good correlation with the expression of these integrins and cytotoxicity
of the cells.
So apoptosis, we saw the cells dying by apoptosis, and you can see here a 10 micromolar, 25 micromolar.
And the caspases, mainly caspase-3 and caspase-9, but not 6 or 8 were affected, were modified
in this cell.
The co-immunoprecipitation assay we used using monoclonal antibodies for lunacin and treating
the cells with 5 micromolar of lunacin, we saw a very interesting effect.
We found the complex between lunacin and alpha-5 antibody here.
So this is what's telling us is that, yeah, there was an interaction between lunacin and
this integrin.
We also saw different times of exposure of the cells to 1 micromolar of lunacin.
We saw that after 24 hours, lunacin was already in the cytoplasm of these colon cancer cells,
and after 72 hours, those were clearly present in the nucleus.
So integrins was, there was an interaction with lunacin, but also lunacin was able to
penetrate the cell and get into the nucleus at this concentration, 1 micromolar.
So we also studied some markers like this kinase and the metabolism related to this
addition kinase, and we noticed at 5 micromolar and 10 micromolar a reduction in all the cancer
cells, but mainly KEM, the very highly metastatic cell, was also affected, in fact.
And also ERK, we noticed a decrease mainly for this cancer cell.
NF-kB, as you know, is a marker of inflammation that is directly correlated with cancer, and
our preliminary studies have shown a clear influence of lunacin on markers of inflammation.
And in this case, we also saw that NF-kB in these colon cancer cells was decreased by
the presence of 5 micromolar of lunacin.
The migration assay also was very interesting.
We obtained about 30% decrease in the migration of the cells when we just used RKO cells.
The other cells were not very easy to test, but these ones were relatively easy, and you
can see here the intensity of the growth of the cells.
So this is doxocycline that we use as a control.
So there is an effect also on mobility, migration of the cells.
From our in vivo study, we also saw interesting correlation and interaction between lunacin
and oxaliplatin.
As you can see here, this is the mean number of liver metastasis.
This is the control PBS, lunacin, oxaliplatin, and the N is oxaliplatin plus lunacin.
So there is a clear synergistic effect due to the presence of lunacin in the microenvironment
for the action of oxaliplatin.
Yes, lunacin and oxaliplatin and their combination increase the number of necrotic cancer cells
as compared to PBS.
Most importantly, it reduced the expression of proliferating cell nuclear antigen.
As you can see here from our in vivo study, almost 90% was reduced, the proliferation
of the nuclear cellular antigen.
And also BCL, proapoptotic cell markers and ASBACs and BCL, both the combination was reduced
in liver tumor secretion derived from this study.
We study also the expression of IKK and phosphorylated P65 and FKB, and as you can see here, there
was a decrease, a direct decrease in this in vivo study.
Well, this is just trying to interact, the interaction of all the markers.
Lunacin seems to interact with one of the integrins or some integrins on the surface
of the cell, and then promote the decrease of cell migration, and as you saw, some of
these markers were downregulated.
We saw in previous studies that nuclear clustering was extremely, like 40 times, 40 times increased.
And finally, we saw a sensitivity of the mitochondria, and finally, caspases increase and produce
the cell, the death of the cell.
So around 25 grams of soy protein per day will give you the concentration that we tested
here in vivo, and now we know that, yes, lunacin, a naturally present peptide in soy, is able
to interact with a receptor such as integrins, and also cause the death of very highly metastatic
cancer cells.
So there are many things to do, and of course, we would like to take this to a potential
translational study in the future.
Very good, thank you.
It's very interesting that you've got this effect with natural peptide.
So you mentioned that 25 grams of soy gives you five micromolar, but is that a dose that's
sustained?
Because in your cell culture media, you presumably have constant five micromolar.
Right, yeah, yeah.
For the animal study, we have to apply it every day, yes.
It's daily.
It's a constant level of lunacin.
Correct, correct, yes.
You mentioned studies that this combines chromatin.
So do you find any, and I looked up some briefly that a couple of the studies show this, do
you find any changes of histone, acetylation, or other things in those sections in the animals
treated to suggest that magnesium is operative in vivo?
Yeah, I mean, we have to do more studies, but preliminary results show the same, yeah,
and that has been shown also in skin cancer, breast cancer.
Those are the two types that have been shown before, but we would like to continue doing
more studies to demonstrate.
So the peptide changes, increases acetylation, and what do you do with that?
Modulates the equilibrium between acetylation and deacetylation.
Any more questions?
Thank you.